Population pharmacokinetic and exposure‐response analyses of pemigatinib in patients with advanced solid tumors including cholangiocarcinoma

• Главные авторы: Xiaohua Gong (Автор), Ayman Akil (Автор), Andre Ndi (Автор), Tao Ji (Автор), Xiang Liu (Автор), Mark Lovern (Автор), Xuejun Chen (Автор)
• Формат: ‌
• Опубликовано: Wiley, 2023-11-01T00:00:00Z.
• Предметы: article
• Online-ссылка: Connect to this object online.

Abstract Pemigatinib is a selective, potent, oral inhibitor of fibroblast growth factor receptor (FGFR)1-3 with efficacy in patients with previously treated, advanced/metastatic cholangiocarcinoma (CCA) with FGFR2 alterations. A previously developed population pharmacokinetic (PK) model of pemigatin...